Abstract
Bispecific antibody (bsAb) is a type of human-modified antibody which two or more sites are capable of binding two or more individual antigens. This dual specificity enables bsAbs to have superior application than the monoclonal antibodies as they can eliminate tumour cells via recruiting T cells and also the accessory immune cells in some cases, as well as can simultaneously block two different signalling pathways or different disease mediator. More than 30 technologies have been applied for the development of bsAbs based on heavy chains and light chains heterologous recombination. However, only three bsAbs have been approved and available on the market, whereas over 110 BsAbs are at different clinical or research stages. In this paper, different types of bsAbs will be elaborated as well as the clinical significance of the approved bsAbs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
